GO
Loading...

Roche Holding AG

More

  • *Novartis sees margins on LCZ696 better than for Diovan. BARCELONA, Sept 1- Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Aug 27- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • NEW YORK, Aug 25- The S&P 500 was unable to hold the 2,000 mark after moving above the milestone level for the first time on Monday, but still managed to close at a record high, buoyed by financials and biotechnology stocks.

  • Burger King and Hovnanian are big market movers Monday, 25 Aug 2014 | 4:28 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Burger King Worldwide Inc., up $5.29 to $32.40. GrubHub Inc., down $3.60 to $39.16.

  • NEW YORK, Aug 25- The S&P 500 briefly hurdled above 2,000 for the first time on Monday, with financials and biotechnology stocks lifting the benchmark index to a record as investors make equities their asset of choice.

  • There's still hunger for 'blockbuster' biotech deals Monday, 25 Aug 2014 | 10:58 AM ET
    Severin Schwan, chief executive officer Roche Holding.

    Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.

  • Biotechs rallied after Roche Holding AG agreed to buy InterMune Inc for $8.3 billion in cash, the latest vote of confidence in a sector that many, including Federal Reserve Chair Janet Yellen, are worried is overvalued. InterMune jumped 36 percent to $73.00, with the Nasdaq Biotech index up 2.4 percent.

  • *Roche to buy InterMune for $8.3 billion. *U.S. investors took cues from Europe, where an index of major shares rose 0.7 percent after European Central Bank President Mario Draghi said Friday the ECB was prepared to respond with available tools if inflation dropped further.

  • US stock futures gain on M&A, hope for ECB stimulus Monday, 25 Aug 2014 | 8:36 AM ET

    U.S. stock-index futures rose on Monday, following European shares higher, as traders digested comments by the Fed's Yellen and the ECB's Draghi.

  • *Roche to buy InterMune for $8.3 billion. *U.S. investors took cues from Europe, where an index of major shares rose 0.7 percent after European Central Bank President Mario Draghi said Friday the ECB was prepared to respond with available tools if inflation dropped further.

  • Roche is buying biotech company InterMune for $74 per share, reports CNBC's Meg Tirrell.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.

  • *Euro STOXX 50 index rises 1.1 percent. LONDON, Aug 25- European shares rose in morning trading on Monday, with market sentiment improving after comments by European Central Bank President Mario Draghi raised expectations of further policy easing.

  • Asia stocks lackluster, US economic data awaited Monday, 25 Aug 2014 | 12:55 AM ET

    The move was the latest milestone in a five-year rally for U.S. stocks, which are enjoying a late-summer revival after dipping earlier this month on concerns about rising geopolitical tensions in Russia and the Middle East.

  • *Deal boosts Roche presence in respiratory medicine. LONDON/ ZURICH, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

  • Roche to buy US biotech firm InterMune for $8.3B Sunday, 24 Aug 2014 | 12:49 PM ET

    BERLIN— Swiss pharmaceutical company Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California- based developer of treatments for lung diseases. The companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, paying $74.00 per InterMune share, Roche said.

  • Roche to purchase InterMune in $8.3 billion deal Sunday, 24 Aug 2014 | 12:27 PM ET

    Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.